Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE

Seoul National University

Status: Unknown

Conditions: Hepatocellular Carcinoma

Treatments: Diagnostic Test: MRI

Study type: Interventional

Funder types: Other

Identifiers

NCT03731910

SNUH-1807-149-957

Details and patient eligibility

About

This study aims to investigate the value of early change at MRI in HCC treated with TARE, for evaluation/prediction of treatment response and prognosis.

Enrollment: 35 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Intermediate or locally advanced HCC according to Hong Kong Liver Cancer guideline
• Scheduled for transarterial radioembolization (TARE)
• sign informed consent

Exclusion criteria

• Any absolute or relative contra-indication of contrast-enhanced MRI
• History of other local treatment before TARE in 3 weeks

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

35 participants in 1 patient group

HCC group

Experimental group

Description:

Participants who are scheduled for TARE for HCC treatment. They undergo MRI three times- before, 1- and 2-week after TARE.

Treatment:

Diagnostic Test: MRI